Wildfire Related Air Pollution Exposure and Cognitive Function Pilot Study (NCT07151235) | Clinical Trial Compass
CompletedNot Applicable
Wildfire Related Air Pollution Exposure and Cognitive Function Pilot Study
United States12 participantsStarted 2025-09-18
Plain-language summary
This study will examine how breathing wildfire-related air pollution (WRAP) for one hour affects healthy adults. The main question the study will answer if the effect of WRAP exposure on p-tau, a blood marker of cognitive decline. The changes in p-tau concentrations after exposure to WRAP will be compared to the changes in p-tau after exposure to clean air.
Participants will:
* Have 2 study visits - one visit with exposure to clean air and one visit with exposure to simulated wildfire smoke
* Have blood drawn before and after each exposure
* Complete cognitive tests and memory tasks before and after each exposure
Who can participate
Age range
18 Years – 40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy
* Non smoker
* Weight at least 110 pounds
* Between ages 18 and 40 years old
Exclusion Criteria:
* Claustrophobia or not comfortable in enclosed spaces.
* Colorblindness.
* Inability to hear verbal instructions.
* Cardiovascular disease which, in the opinion of the investigator, would elevate the participant's risk of adverse effects to WRAP exposure. This includes a history of stroke.
* Diabetes requiring the use of insulin.
* Pregnancy (A pregnancy test will be provided to you).
* Current asthma (an asthma attack within the past five years).
* History of childhood asthma.
* Medications which may affect cognition such as beta-blockers and CNS depressants.
* Respiratory symptoms in the previous 4 weeks (cough, wheezing, shortness of breath, etc.) which, in the opinion of the investigator, would elevate the participant's risk of adverse effects to WRAP exposure.
* Use of sedating cold/allergy medications in the previous week.
* Use of marijuana in the previous week.
* Consumption of alcohol in the previous 24 hours.
* Kidney or liver disease.
* Thyroid disease.
* High blood pressure.
* Cancer.
* Parkinson's disease.
* Pacemaker.
* Hay fever.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes in plasma P-tau 217 concentration from pre-exposure to post-exposure
Timeframe: Immediately before, immediately after each exposure
Trial details
NCT IDNCT07151235
SponsorRutgers, The State University of New Jersey